The Psychosis Risk Syndrome Clinic (PRIME) is the recipient of a grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) that will allow the clinic to provide four more years of service.
The PRIME clinic treats young people at clinical high risk for psychosis and aims to identify young people at risk early so that clinicians can intervene as early as possible, should patients develop full-blown psychosis.
“This iteration of PRIME will also include a partnership with several non-Yale-affiliated local mental health clinics, which will begin universal screening of all incoming patients and automatic referral to PRIME,” said Albert Powers, MD, PhD, assistant professor of psychiatry and medical and associate director at the PRIME clinic.
“This will serve to streamline the process of getting patients specialized care as quickly as possible. Of course, in addition to receiving care through PRIME, patients will have the opportunity to participate in an array of cutting-edge research programs aimed at understanding and predicting the onset of psychosis.”
SAMHSA is the agency within the US Department of Health and Human Services that leads public health efforts to advance the behavioral health of the nation. SAMHSA's mission is to reduce the impact of substance abuse and mental illness on America’s communities.